Intended for healthcare professionals

Rapid response to:

Practice BMJ Learning

Malaria: an update on treatment of adults in non-endemic countries

BMJ 2006; 333 doi: (Published 27 July 2006) Cite this as: BMJ 2006;333:241

Rapid Response:

Re: Artesunate for severe malaria

Dear sirs,

Médecins Sans Frontières has recently conducted a formal GMP audit of
the only production facility of artesunate for injection, Guilin
Pharmaceutical Co. (GPC) in China. After some minor follow up work done by
GPC, we are confident to state that the production facilities for
artesunate injection and its solvent, comply fully with GMP. Medecins Sans
Frontieres will soon implement artesunate for injections in its world-wide
malariaprograms as the drug of first choice for severe malaria. We hope
that other organizations and institutions will not hesitate to also start
using this product. Access to the MSF GMP assessment report can given via

Competing interests:
None declared

Competing interests: No competing interests

02 August 2006
margriet l den boer
Amsterdam 1001EA